ANAB - AnaptysBio Inc Stock Price, Fair Value and News

19.87USD-1.60 (-7.45%)Market Closed

Market Summary

USD19.87-1.60

Market Closed

-7.45%

ANAB Alerts

1 major insider sales recently.

ANAB Stock Price

View Fullscreen

ANAB RSI Chart

ANAB Valuation

Market Cap

574.6M

Price/Earnings (Trailing)

-3.51

Price/Sales (Trailing)

33.49

EV/EBITDA

-3.31

Price/Free Cashflow

-4.73

ANAB Price/Sales (Trailing)

ANAB Profitability

EBT Margin

-681.93%

Return on Equity

-185.71%

Return on Assets

-36.17%

Free Cashflow Yield

-21.16%

ANAB Fundamentals

ANAB Revenue

Revenue (TTM)

18.9M

Rev. Growth (Yr)

-51.89%

Rev. Growth (Qtr)

-34.82%

ANAB Earnings

Earnings (TTM)

-163.6M

Earnings Growth (Yr)

-59.81%

Earnings Growth (Qtr)

-13.14%

Breaking Down ANAB Revenue

Last 7 days

-3.1%

Last 30 days

-7.2%

Last 90 days

-9.3%

Trailing 12 Months

-3.4%

How does ANAB drawdown profile look like?

ANAB Financial Health

Current Ratio

10.87

ANAB Investor Care

Buy Backs (1Y)

4.18%

Diluted EPS (TTM)

-6.08

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	14.4M	18.0M	20.6M	17.2M
2022	50.0M	36.7M	23.5M	10.3M
2021	71.2M	101.3M	122.2M	63.2M
2020	23.0M	18.0M	18.0M	75.0M
2019	0	7.5M	10.0M	8.0M
2018	0	0	3.3M	5.0M
2017	0	18.8M	13.0M	1.6M
2016	17.3M	17.1M	16.9M	16.7M
2015	0	0	0	17.6M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of AnaptysBio Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 26, 2024	faga daniel	sold (taxes)	-7,504,730	21.6	-347,441	ceo
Mar 25, 2024	faga daniel	sold	-64,267	21.4225	-3,000	ceo
Mar 22, 2024	faga daniel	sold	-3,325,180	22.7846	-145,940	ceo
Feb 16, 2024	loumeau eric j	sold	-125,000	25.00	-5,000	chief legal officer
Feb 16, 2024	loumeau eric j	acquired	70,100	14.02	5,000	chief legal officer
Jan 30, 2024	mulroy dennis	sold	-72,425	23.6298	-3,065	chief financial officer
Jan 08, 2024	loumeau eric j	sold	-50,272	21.81	-2,305	chief legal officer
Jan 08, 2024	lizzul paul f.	sold	-55,702	21.81	-2,554	chief medical officer
Jan 08, 2024	faga daniel	sold	-149,747	21.81	-6,866	ceo
Jan 08, 2024	mulroy dennis	sold	-47,545	21.81	-2,180	chief financial officer

Which funds bought or sold ANAB recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 12, 2024	Westend Capital Management, LLC	new	-	653	653	-%
Apr 09, 2024	MASSMUTUAL TRUST CO FSB/ADV	unchanged	-	13.00	270	-%
Apr 09, 2024	MATHER GROUP, LLC.	new	-	2,785	2,785	-%
Apr 05, 2024	GAMMA Investing LLC	added	40.00	119	473	-%
Apr 05, 2024	CWM, LLC	added	63.16	1,000	1,000	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	added	590	1,298	1,478	-%
Mar 11, 2024	VANGUARD GROUP INC	reduced	-18.95	-1,019,880	29,562,100	-%
Mar 05, 2024	Fisher Asset Management, LLC	added	0.71	255,193	1,524,140	-%
Mar 01, 2024	GOLDMAN SACHS GROUP INC	added	56.39	2,772,140	5,976,220	-%
Feb 28, 2024	AMERICAN INTERNATIONAL GROUP, INC.	reduced	-0.41	31,537	199,463	-%

Are Funds Buying or Selling ANAB?

Are funds buying ANAB calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own ANAB

No. of Funds

ANAB Alerts

1 major insider sales recently.

Unveiling AnaptysBio Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	deep track capital, lp	7.67%	2,036,990	SC 13G/A
Feb 14, 2024	point72 asset management, l.p.	3.0%	788,545	SC 13G/A
Feb 14, 2024	tang capital partners lp	7.3%	1,950,609	SC 13G/A
Feb 13, 2024	vanguard group inc	5.19%	1,380,115	SC 13G/A
Jan 26, 2024	blackrock inc.	6.8%	1,799,823	SC 13G/A
Oct 02, 2023	deep track capital, lp	5.12%	1,360,176	SC 13G
Feb 14, 2023	point72 asset management, l.p.	7.5%	2,124,200	SC 13G/A
Feb 10, 2023	flynn james e	4.09%	1,161,826	SC 13G/A
Feb 09, 2023	federated hermes, inc.	4.93%	1,401,559	SC 13G/A
Feb 09, 2023	vanguard group inc	6.25%	1,776,908	SC 13G/A

Recent SEC filings of AnaptysBio Inc

View All Filings

Date Filed	Form Type	Document
Mar 26, 2024	4	Insider Trading
Mar 11, 2024	10-K	Annual Report
Mar 11, 2024	8-K	Current Report
Mar 11, 2024	S-8	Employee Benefits Plan
Feb 21, 2024	4	Insider Trading
Feb 16, 2024	144	Notice of Insider Sale Intent
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 14, 2024	SC 13G/A	Major Ownership Report
Feb 13, 2024	SC 13G/A	Major Ownership Report

Peers (Alternatives to AnaptysBio Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	39.5B	6.8B	-0.79%	-27.48%	-8.38	5.77	-64.45%	-156.37%
HILS	22.4B	152.6K	-0.77%	465779.94%	-2.4K	146.8K	-	-9.98%
ALNY	18.3B	1.8B	-1.45%	-27.97%	-41.56	10.01	76.23%	61.08%
BMRN	17.1B	2.4B	7.98%	-8.04%	101.85	7.06	15.42%	18.43%
INCY	11.8B	3.7B	-8.07%	-28.58%	19.8	3.2	8.87%	75.42%
MID-CAP
APLS	5.8B	396.6M	-14.74%	-41.61%	-10.96	14.6	425.83%	18.94%
BBIO	4.4B	-	-10.03%	65.15%	-6.72	60.35	54.84%	-34.79%
AXSM	3.3B	270.6M	-3.97%	-4.38%	-13.8	12.2	440.80%	-27.84%
ACAD	2.8B	726.4M	-8.12%	-12.78%	-46.22	3.9	40.45%	71.62%
ARWR	2.8B	240.7M	-19.94%	-25.89%	-9.4	12.18	-1.03%	-92.09%
SMALL-CAP
CPRX	1.9B	398.2M	-0.50%	-10.21%	26.41	4.74	85.90%	-14.05%
NVAX	544.4M	983.7M	-24.32%	-58.17%	-1	0.55	-50.36%	17.16%
CRBP	389.6M	881.7K	-10.79%	209.42%	-8.73	466.16	-77.61%	-5.33%
INO	258.5M	4.9M	3.17%	4.73%	-1.91	53.11	-54.97%	51.71%
IBIO	6.6M	2.1M	79.05%	74.07%	-0.24	2.14	-13.45%	66.37%

AnaptysBio Inc News

Latest updates

AnaptysBio Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

Income Statement (Quarterly)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4	2018Q3
Revenue	-34.8%	3,164,000	4,854,000	4,653,000	4,486,000	6,576,000	2,262,000	1,107,000	1,059,000	1,011,000	20,890,000	30,027,000	11,247,000	60,000,000	-	-	15,000,000	3,000,000	-	5,000,000	-	5,000,000
Operating Expenses	24.6%	51,140,000	41,050,000	43,603,000	45,775,000	32,781,000	30,926,000	29,015,000	32,719,000	32,168,000	27,653,000	30,560,000	29,608,000	26,655,000	24,336,000	22,635,000	25,253,000	25,258,000	33,745,000	31,657,000	19,663,000	21,887,000
S&GA Expenses	1.0%	10,276,000	10,172,000	10,680,000	10,818,000	9,407,000	8,862,000	8,171,000	10,203,000	5,392,000	5,432,000	5,246,000	5,423,000	5,088,000	4,794,000	4,687,000	4,285,000	3,832,000	3,814,000	4,307,000	3,743,000	4,004,000
R&D Expenses	-100.0%	-	30,878,000	32,923,000	34,957,000	23,374,000	22,064,000	20,844,000	22,516,000	26,776,000	22,221,000	25,314,000	24,185,000	21,567,000	19,542,000	17,948,000	20,968,000	21,426,000	29,931,000	27,350,000	15,920,000	17,883,000
EBITDA Margin	-9.0%	-6.78	-6.22	-7.12	-8.87	-12.45	-2.43	-1.56	-1.14	-0.91	-0.16	-0.19	-0.27	-	-	-	-	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	4,000	200,000	240,000	281,000	365,000	400,000
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-22,000	-51,000	-60,000	-192,000	-
Earnings Before Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-	33,646,000	-23,767,000	-21,548,000	-8,262,000	-20,285,000	-31,084,000	-24,022,000	-17,186,000	-15,958,000
EBT Margin	-9.0%	-6.82	-6.26	-7.16	-8.92	-12.51	-2.46	-1.57	-1.16	-0.91	-0.16	-0.20	-0.28	-	-	-	-	-	-	-	-	-
Net Income	-13.1%	-42,211,000	-37,308,000	-39,845,000	-44,255,000	-26,413,000	-33,502,000	-32,554,000	-36,255,000	-32,538,000	-6,666,000	-429,000	-18,163,000	33,646,000	-23,767,000	-21,548,000	-8,262,000	-20,263,000	-31,033,000	-23,962,000	-16,994,000	-15,958,000
Net Income Margin	-20.6%	-8.67	-7.19	-8.01	-9.47	-12.51	-5.74	-2.94	-1.52	-0.91	0.07	-0.09	-0.42	-	-	-	-	-	-	-	-	-
Free Cashflow	5.5%	-34,629,000	-36,636,000	-25,599,000	-24,743,000	-10,860,000	-17,797,000	-24,225,000	-21,069,000	-25,315,000	-7,178,000	8,728,000	-23,521,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-7.2%	452	487	517	552	610	619	604	625	643	424	427	396	417	385	402	424	435	452	480	494	509
Current Assets	-4.9%	407	428	439	437	447	450	453	512	554	387	398	387	397	346	385	371	378	425	431	422	434
Cash Equivalents	36.8%	36.00	26.00	35.00	95.00	71.00	59.00	72.00	166	496	336	332	284	251	209	221	165	171	183	147	106	114
Net PPE	-6.9%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	1.00	2.00	2.00	2.00	1.00	2.00	1.00
Current Liabilities	-4.4%	37.00	39.00	42.00	36.00	26.00	21.00	20.00	20.00	16.00	21.00	21.00	14.00	20.00	24.00	20.00	23.00	30.00	30.00	31.00	25.00	22.00
Shareholder's Equity	-26.8%	88.00	120	148	191	262	278	304	331	356	384	386	382	397	360	381	401	405	421	448	468	486
Retained Earnings	-7.4%	-614	-571	-534	-494	-450	-424	-390	-358	-321	-289	-282	-282	-263	-297	-273	-252	-244	-223	-192	-168	-146
Additional Paid-In Capital	1.2%	703	695	687	689	718	708	699	691	679	673	668	664	661	658	654	652	649	644	641	637	633
Shares Outstanding	0.1%	27.00	27.00	27.00	27.00	29.00	28.00	28.00	28.00	27.00	27.00	27.00	27.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	367	-	-	-	400	-	-	-	489	-	-	-	556	-	-	-	1,391	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	5.8%	-34,349	-36,474	-25,409	-24,568	-10,685	-17,747	-24,147	-21,014	-25,301	-7,006	9,591	-23,204	37,578	-17,013	-19,610	-15,112	-15,805	-22,096	-15,517	-16,099	-12,290
Share Based Compensation	342.6%	13,278	3,000	2,900	8,860	10,200	3,000	2,900	7,742	3,978	4,364	3,690	3,315	-	-	-	-	-	-	-	-	-
Cashflow From Investing	60.5%	49,178	30,635	-20,455	85,396	21,497	-32,434	-70,996	-312,912	-66,694	10,839	37,961	56,729	3,598	4,732	75,394	10,751	4,035	59,863	57,876	9,657	-166,150
Cashflow From Financing	-67.9%	-5,159	-3,072	-13,492	-37,574	1,949	37,027	432	4,609	251,336	241	554	167	126	263	71.00	-1,339	-111	-1,421	-1,660	-1,301	-1,372
Buy Backs	-1665.4%	-229	-13.00	11,656	38,816	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

ANAB Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022	Dec. 31, 2021
Income Statement [Abstract]
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	Collaboration Revenue [Member]	Collaboration Revenue [Member]	Collaboration Revenue [Member]
Collaboration revenue	$ 17,157,000	$ 10,287,000	$ 63,175,000
Operating expenses:
Research and development	132,283,000	88,798,000	98,496,000
General and administrative	41,946,000	36,643,000	21,493,000
Acquired in-process research and development	7,339,000	0	0
Total operating expenses	181,568,000	125,441,000	119,989,000
Loss from operations	(164,411,000)	(115,154,000)	(56,814,000)
Other income (expense), net:
Interest income	18,873,000	7,550,000	431,000
Non-cash interest expense for the sale of future royalties	(18,083,000)	(21,108,000)	(1,450,000)
Other (expense) income, net	(2,000)	12,000	37,000
Total other income (expense), net	788,000	(13,546,000)	(982,000)
Loss before income taxes	(163,623,000)	(128,700,000)	(57,796,000)
Benefit (Provision) for income taxes	4,000	(24,000)	0
Net loss	(163,619,000)	(128,724,000)	(57,796,000)
Other comprehensive loss:
Unrealized gain (loss) on available for sale securities	4,449,000	(4,824,000)	(418,000)
Comprehensive loss	$ (159,170,000)	$ (133,548,000)	$ (58,214,000)
Net loss per common share:
Basic (in dollars per share)	$ (6.08)	$ (4.57)	$ (2.11)
Diluted (in dollars per share)	$ (6.08)	$ (4.57)	$ (2.11)
Weighted-average number of shares outstanding:
Basic (in shares)	26,924	28,165	27,431
Diluted (in shares)	26,924	28,165	27,431

ANAB Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 35,965	$ 71,308
Receivables from collaborative partners	6,851	1,419
Short-term investments	354,939	369,933
Prepaid expenses and other current assets	9,080	4,545
Total current assets	406,835	447,205
Property and equipment, net	2,098	2,089
Operating lease right-of-use assets	16,174	17,898
Long-term investments	27,026	142,935
Other long-term assets	256	256
Total assets	452,389	610,383
Current liabilities:
Accounts payable	4,698	2,784
Accrued expenses	30,967	21,633
Current portion of operating lease liability	1,777	1,637
Total current liabilities	37,442	26,054
Liability related to sale of future royalties	310,807	304,413
Operating lease liability, net of current portion	16,037	17,813
Stockholders’ equity:
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares, issued or outstanding at December 31, 2023 and December 31, 2022, respectively	0	0
Common stock, $0.001 par value, 500,000 shares authorized, 26,597 shares and 28,513 shares issued and outstanding at December 31, 2023 and December 31, 2022, respectively	27	29
Additional paid in capital	702,969	717,797
Accumulated other comprehensive loss	(797)	(5,246)
Accumulated deficit	(614,096)	(450,477)
Total stockholders’ equity	88,103	262,103
Total liabilities and stockholders’ equity	$ 452,389	$ 610,383

About AnaptysBio Inc

AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 trial for the treatment of generalized pustular psoriasis; Rosnilimab, an anti-PD-1 agonist antibody program designed to suppress T-cell driven inflammatory diseases by augmenting signaling through PD-1 or targeted depletion of PD-1+ T cells; and ANB032, an anti-BTLA modulator antibody applicable to human inflammatory diseases associated with lymphoid and myeloid immune cell dysregulation. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. and Bristol-Myers Squibb; and license agreements with United Kingdom Research and Innovation, as well as Millipore Corporation. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.

CEO	Mr. Daniel R. Faga
WEBSITE	anaptysbio.com
INDUSTRY	Biotechnology
EMPLOYEES	96

AnaptysBio Inc Frequently Asked Questions

What is the ticker symbol for AnaptysBio Inc? What does ANAB stand for in stocks?

ANAB is the stock ticker symbol of AnaptysBio Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of AnaptysBio Inc (ANAB)?

As of Wed Apr 17 2024, market cap of AnaptysBio Inc is 574.6 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ANAB stock?

You can check ANAB's fair value in chart for subscribers.

What is the fair value of ANAB stock?

You can check ANAB's fair value in chart for subscribers. The fair value of AnaptysBio Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of AnaptysBio Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ANAB so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is AnaptysBio Inc a good stock to buy?

The fair value guage provides a quick view whether ANAB is over valued or under valued. Whether AnaptysBio Inc is cheap or expensive depends on the assumptions which impact AnaptysBio Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ANAB.

What is AnaptysBio Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Apr 17 2024, ANAB's PE ratio (Price to Earnings) is -3.51 and Price to Sales (PS) ratio is 33.49. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ANAB PE ratio will change depending on the future growth rate expectations of investors.